

- 3 -

LI *et al.*  
Appl. No. 09/515,513***Amendments to the Claims***

The listing of claims will replace all prior versions, and listings of claims in the application.

1-46. (cancelled).

47. (currently amended) A method for synthesizing one or more cDNA molecules comprising combining one or more mRNA templates, or one or more poly A RNA templates and a primer with at least one polypeptide having reverse transcriptase activity and an antibody or antibody fragment inhibitor of the polypeptide having reverse transcriptase activity, incubating said template, primer, polypeptide and inhibitor at a temperature between 10°C and 90°C, wherein said inhibitor inhibits said reverse transcriptase activity at said temperature; and elevating the temperature of said template, primer, polypeptide and inhibitor ~~to a temperature between 10°C and 90°C to inactivate~~ thereby inactivating said inhibitor, whereby one or more cDNA molecules are synthesized.

48. (canceled)

49. (previously presented) The method of claim 47, wherein said antibody or antibody fragment is polyclonal or monoclonal.

50. (canceled)

Atty. Dkt. No. 0942.4870001/RWE/AWL

- 4 -

LI *et al.*  
Appl. No. 09/515,513

51. (previously presented) The method of claim 47, wherein said polypeptide is a reverse transcriptase selected from the group consisting of Moloney Murine Leukemia Virus reverse transcriptase (M-MLV RT), Rous Sarcoma Virus reverse transcriptase (RSV RT), Avian myeloblastosis Virus reverse transcriptase (AMV RT), Rous associated Virus reverse transcriptase (RAV RT), Myeloblastosis associated virus reverse transcriptase (MAV RT) and Human Immunodeficiency Virus reverse transcriptase (HIV RT), and fragments thereof having reverse transcriptase activity.

52. (previously presented) The method of claim 51, wherein said reverse transcriptase is reduced in RNase H activity.

53. (previously presented) The method of claim 47, wherein said inhibitor inhibits, prevents, or reduces internal priming.

54. (previously presented) The method of claim 53, wherein said temperature is within the range of about 10-65 °C.

55. (previously presented) The method of claim 53, wherein said temperature is within the range of about 10-55 °C.

56. (previously presented) The method of claim 53, wherein said temperature is within the range of about 10-45 °C.

Atty. Dkt. No. 0942.4870001/RWE/AWL

- 5 -

LI *et al.*  
Appl. No. 09/515,513

57. (previously presented) The method of claim 47, wherein the primer to template ratio is between 12:1 and 1:12.

58. (previously presented) The method of claim 57, wherein said primer to template ratio is between 10:1 and 1:10.

59. (previously presented) The method of claim 57, wherein said primer to template ratio is between 5:1 and 1:5.

60. (previously presented) The method of claim 47, wherein said primer has a length of between 20 and 100 bases.

61. (previously presented) The method of claim 60, wherein said length is between 20 and 75 bases.

62. (previously presented) The method of claim 60, wherein said length is between 20 and 50 bases.

63. (previously presented) The method of claim 60, wherein said length is between 25 and 35 bases.

64-105 (cancelled).

Atty. Dkt. No. 0942.4870001/RWE/AWL

SEP. 22. 2005 10:15AM

SKG&F3712540

NO. 0178 P. 7

PAGE 7/10 \* RCVD AT 9/22/2005 11:30:20 AM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-6/28 \* DNIS:2730751 \* CSID:202 218 7813 \* DURATION (mm-ss):01-56

**THIS PAGE BLANK (USPTO)**

- 7 -

LI *et al.*  
Appl. No. 09/515,513

114. (currently amended) Then method of claim 112, wherein said reverse transcriptase is selected from the group consisting of SUPERScript™ (mutant M-MLV RT having reduced RNase H activity), SUPERScript™ II (mutant M-MLV RT having reduced RNase H activity), THERMOScript™ (mutant AMV RT having reduced RNase H activity) and THERMOScript™ II (mutant AMV RT having reduced RNase H activity).

115. (previously presented) The method of claim 47, wherein said one or more mRNA templates is a population of mRNA templates suitable for the production of a cDNA library.

116. (previously presented) The method of claim 47, wherein said cDNA molecules are a cDNA library.

117. (previously presented) The method of claim 53, wherein said temperature is within the range of about 10-35°C.

118. (previously presented) The method of claim 47, wherein said primer is an oligo(dT) primer.

Atty. Dkt. No. 0942.4870001/RWE/AWL

SEP. 22. 2005 10:16AM

SKG&F3712540

NO. 0178 P. 9

PAGE 9/10 \* RCVD AT 9/22/2005 11:30:20 AM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-6/28 \* DNIS:2730751 \* CSID:202 218 7813 \* DURATION (mm-ss):01-56

**THIS PAGE BLANK (USPTO)**

- 9 -


LI et al.  
Appl. No. 09/515,513**Conclusion**

All of the stated grounds of rejection have been properly traversed, accommodated, or rendered moot. Applicants believe that a full and complete reply has been made to the outstanding Office Action and, as such, the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt and favorable consideration of this Amendment and Reply is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
Robert W. Esmond  
Attorney for Applicants  
Registration No. 32,893

Date: September 22, 2005

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

425004\_1.DOC

Atty. Dkt. No. 0942.4870001/RWE/AWL